Wells Fargo keeps Inspire Medical at Equal-Weight and lifts price target to $69
According to TradingView, Wells Fargo kept its Equal-Weight rating on Inspire Medical Systems and raised its price target from $56 to $69, up 23.2%.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Wells Fargo kept its Equal-Weight rating on Inspire Medical Systems shares and raised the price target from $56 to $69, a 23.2% increase. According to TradingView, the new target implies roughly 2.7% upside from the November 2 close of $67.21.
The same report lists recent analyst notes from the past 30 days. Across the five most recent, targets range from $60 to $78. The firms include Evercore ISI Group, Barclays, Piper Sandler, Baird and Truist Securities.
why it matters
Rating and target changes like this are routine and reflect one analyst's view rather than new company data. The spread of $60 to $78 across recent notes shows that analysts do not agree on the fair value of Inspire Medical shares.
tags
instruments
sources
- Wells Fargo maintains Inspire Medical Systems at Equal-Weight, raises price target to $69 from $56 — TradingView, 3 November 2026 at 15:27 UTC
- Wells Fargo maintains Ibotta at Equal-Weight, raises price target to $49 from $40 — TradingView, 3 November 2026 at 15:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗